HXL Stock Overview
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hexima Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.011 |
| 52 Week High | AU$0.022 |
| 52 Week Low | AU$0.01 |
| Beta | 0.65 |
| 1 Month Change | 10.00% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| HXL | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -1.5% |
| 1Y | 0% | -7.4% | 5.7% |
Return vs Industry: HXL exceeded the Australian Biotechs industry which returned -7.4% over the past year.
Return vs Market: HXL underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
| HXL volatility | |
|---|---|
| HXL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: HXL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HXL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Geoffrey Kempler | hexima.com.au |
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company’s lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.
Hexima Limited Fundamentals Summary
| HXL fundamental statistics | |
|---|---|
| Market cap | AU$1.84m |
| Earnings (TTM) | -AU$753.18k |
| Revenue (TTM) | AU$193.86k |
9.5x
P/S Ratio-2.4x
P/E RatioIs HXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HXL income statement (TTM) | |
|---|---|
| Revenue | AU$193.86k |
| Cost of Revenue | AU$17.10k |
| Gross Profit | AU$176.76k |
| Other Expenses | AU$929.94k |
| Earnings | -AU$753.18k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0045 |
| Gross Margin | 91.18% |
| Net Profit Margin | -388.53% |
| Debt/Equity Ratio | 0% |
How did HXL perform over the long term?
See historical performance and comparison